AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34306274
Drug: Multidimensional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional treatment (MT) group, n = 30
Trial: 34306274
Drug: Unimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unimodal treatment (UT) group, n = 30
Trial: 35352373
Drug: Gluten (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten (10 g in two granola bars for 7 days)
Trial: 32244279
Drug: Multivitamins (containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamins (containing 50 µg vitamin B12)
Trial: 35763357
Drug: Levosimendan 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 0.1 mcg/kg/min from anesthetic induction
Trial: 35763357
Drug: Milrinone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone 0.5 mcg/kg/min (control)
Trial: 36443540
Drug: Non-chemotherapy
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-chemotherapy
Trial: 32710888
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) with normal daily habits
Trial: 34649590
Drug: 10 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weekly sessions of virtually delivered qualified exercise professional (QEP) support
Trial: 34649590
Drug: 10 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weekly sessions of virtually delivered QEP support
Trial: 32291982
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 1.0 g TXA before operation (Group B)
Trial: 32291982
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 1.0 g TXA before operation combined with local use of TXA cocktail during operation (Group C)
Trial: 32291982
Drug: No TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No TXA administered (Group A)
Trial: 33653410
Drug: Emotion regulation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion regulation training (eight 90-min sessions, one session weekly)
Trial: 34670026
Drug: Deep Brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep Brain Stimulation (DBS) of the ventral capsule/ventral striatum (VC/VS)
Trial: 32591421
Drug: Fructose (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (20 g) intake 30 minutes prior to exercise
Trial: 35522900
Drug: ATx201 OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATx201 OINTMENT 2%
Trial: 33393175
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BT) injection
Trial: 38923910
Drug: Chemotherapy (Chemo)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Chemo)
Trial: 33317621
Drug: MSI-195 (400,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSI-195 (400, 800, and 1600 mg)
Trial: 32506228
Drug: S. salivarius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. salivarius K12 lozenge
Trial: 34272087
Drug: Systemic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapies
Trial: 34514495
Drug: Free diet
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free diet and single donor standard faecal transplantation (FT) by colonoscopy on Day 1 and rectal enemas on Days 2 and 14 without dietary conditioning of the donor.
Trial: 33795297
Drug: Weekly teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly teriparatide injections (40 ?g/week)
Trial: 39555822
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation
Trial: 34711071
Drug: Weekly follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly follow-up meetings
Trial: 33512387
Drug: OMT +
RxNorm normalized name: Omtryg
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMT + medication group
Trial: 32862437
Drug: Dexmedetomidine (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (3.5 µg/kg followed by 7 µg/kg/h) administered before ischaemia (preconditioning)
Trial: 32862437
Drug: Dexmedetomidine (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (3.5 µg/kg followed by 7 µg/kg/h) administered after beginning ischaemia (post-conditioning)
Trial: 35742717
Drug: Trauma-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive behavioral therapy
Trial: 34400865
Drug: Community pharmacy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community pharmacy-based medication therapy management programme
Trial: 35562420
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation among patients using calcium channel blockers
Trial: 33746216
Drug: PUFAs supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFAs supplementation (1000 mg daily)
Trial: 33493448
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin sodium 25,000 IU in 5 mL, administered every 6 hours for 10 days via nebuliser
Trial: 33493448
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin sodium 25,000 IU in 5 mL
Trial: 34148172
Drug: Oral Neomycin
RxNorm normalized name: neomycin Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Neomycin and Bacitracin (OIVA group)
Trial: 34148172
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (IVA group)
Trial: 34148172
Drug: OIVA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OIVA with mechanical bowel preparation (MBP)
Trial: 34148172
Drug: IVA with
RxNorm normalized name: Floriva with 0.25mg Fluoride and Vitamin D Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVA with mechanical bowel preparation (MBP)
Trial: 34411060
Drug: Droperidol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (20 ?g/kg)
Trial: 33735275
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (high frequency) - multiple component incentive for home testing, attendance of weekly telephone education classes and absolute HbA1c reduction
Trial: 35233748
Drug: Glycyrrhizin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhizin (60 mg) and Boswellic acids (200 mg) twice daily for 14 days
Trial: 32804205
Drug: Erythropoietin 1000
RxNorm normalized name: ERYTHROPOIETIN 10000 UNT/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin 1000 U/kg every 48 hours for 6 doses, followed by 400 U/kg 3 times a week through postmenstrual age of 32 weeks.
Trial: 32804205
Drug: Placebo (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham injections).
Trial: 34518263
Drug: Micronised purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised purified flavonoid fraction (MPFF, Venixxa) 1000 mg orally for 6 months
Trial: 35421233
Drug: RRB (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRB (125 g fresh equivalents) daily
Trial: 35421233
Drug: RRB +
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: RRB + FOS (8g) daily
Trial: 34918028
Drug: EFV1 (efavirenz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV1 (efavirenz with TB treatment containing rifapentine 1200mg, isoniazid, pyrazinamide, and either ethambutol or moxifloxacin)
Trial: 34918028
Drug: EFV2 (newly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV2 (newly initiating efavirenz with TB treatment containing rifapentine 1200mg, isoniazid, pyrazinamide, and either ethambutol or moxifloxacin)
Trial: 32767506
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei TH14 (105 cfu/kg FM) + cellulase (10,000 unit/kg FM) + molasses (50 g/kg FM)
Trial: 32767506
Drug: Cellulase (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellulase (10,000 unit/kg FM) + molasses (50 g/kg FM)
Trial: 32767506
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei TH14 (105 cfu/kg FM) + molasses (50 g/kg FM)
Trial: 36036095
Drug: Clustered missed
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clustered missed doses
Trial: 36036095
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment days missed
Trial: 34137446
Drug: Meta-analysis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meta-analysis of fibrin patch
Trial: 35799553
Drug: Triidothyronine 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triidothyronine 1 mic/kg 10 doses 8th hourly given orally postoperatively
Trial: 35946332
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine and subcutaneous morphine (rapid titration)
Trial: 35946332
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine (control)
Trial: 36737698
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg triamcinolone acetonide
Trial: 35179323
Drug: Darolutamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darolutamide (600 mg twice daily)
Trial: 34692441
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg daily for 10 days
Trial: 34060988
Drug: Cuyuxunxi (CYXX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuyuxunxi (CYXX) prescription
Trial: 34601551
Drug: Medium-dose spice
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose spice diet (MSD) 3.285 g · d‐1 · 2100 kcal‐1 for 4 weeks
Trial: 34601551
Drug: High-dose spice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose spice diet (HSD) 6.571 g · d‐1 · 2100 kcal‐1 for 4 weeks
Trial: 32060566
Drug: 50 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg/day VK2
Trial: 32060566
Drug: 90 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 µg/day VK2
Trial: 32060566
Drug: Co-supplementation with
RxNorm normalized name: zinc bandage with supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-supplementation with calcium (500 mg/day) and vitamin D3 (10 µg/day)
Trial: 33040841
Drug: Trazodone/gabapentin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone/gabapentin combination (2.5/25, 10/100, 30/300)
Trial: 33040841
Drug: Trazodone/gabapentin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone/gabapentin combination (10/100)
Trial: 34914338
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 250 mg daily (AA250 arm)
Trial: 34914338
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 500 mg daily (AA500 arm)
Trial: 34996918
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml DW5
Trial: 33105146
Drug: Liraglutide (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (titrated to maximum tolerable dose up to 1.8 mg)
Trial: 35599918
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (4000 IU weekly)
Trial: 33522909
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of cefazolin
Trial: 33289350
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg FT-4101
Trial: 35565738
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg gluten
Trial: 35565738
Drug: Gluten administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten administration (all doses)
Trial: 34529686
Drug: No intervention/treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention/treatment as usual
Trial: 35392153
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 µg/ml)
Trial: 35392153
Drug: Sufentanyl (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanyl (0.4 µg/ml)
Trial: 34978861
Drug: Quadpill containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadpill containing quarter doses of 4 blood pressure drugs
Trial: 34978861
Drug: Standard-dose monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose monotherapy
Trial: 35346485
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 to 100 mg)
Trial: 35346485
Drug: Standard hypotensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hypotensive treatment (ST)
Trial: 34741544
Drug: Nurse-led MBSR
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led MBSR therapy + regular diabetes education
Trial: 33280397
Drug: Self-applied acupressure
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-applied acupressure in combination with usual treatment
Trial: 33331798
Drug: Nutraceutical (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical (combination of soy isoflavone, black cohosh, chasteberry, and evening primrose oil extracts)
Trial: 33223141
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of sevoflurane
Trial: 33223141
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of sevoflurane
Trial: 32232615
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with 106 cfu/mL/kg Lactobacillus acidophilus
Trial: 32232615
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (0 cfu/mL/kg Lactobacillus acidophilus)
Trial: 32119591
Drug: lyophilized TAK-003
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lyophilized TAK-003 formulation
Trial: 32119591
Drug: liquid TAK-003
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid TAK-003 formulation
Trial: 35932073
Drug: Nurse-led integrative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led integrative medicine-based structured education program (4 weeks)
Trial: 33423620
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (ET) consisting of aerobic, strengthening and stretching exercises, 2 days/week for 6 weeks in addition to compression therapy (CT)
Trial: 33423620
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy (CT) only
Trial: 32532356
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of dental pulp stem cells suspension (3.0x10^7 human DPSCs in 30ml saline solution) on days 1, 4, and 7
Trial: 32532356
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment for COVID-19
Trial: 36448255
Drug: Absorbable polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorbable polysaccharide hemostatic agent
Trial: 36448255
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hemostatic agent)
Trial: 38713475
Drug: Therapeutic Drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic Drug Monitoring (TDM)
Trial: 35544149
Drug: MucoRice-CTB 6
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MucoRice-CTB 6 g
Trial: 35544149
Drug: MucoRice-CTB (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MucoRice-CTB (any dose)
Trial: 35544149
Drug: Placebo (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (any dose)
Trial: 33403743
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (MPG/phototherapy and PRP-assisted)
Trial: 35731529
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) 1000 mg on days 1 and 15, 500 mg maintenance at months 12 and 18
Trial: 35731529
Drug: Anti-desmoglein 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-desmoglein 3 antibodies (DSG3 Abs) levels
Trial: 32024533
Drug: Intra-arterial administration
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial administration of 177Lu-DOTATATE
Trial: 32024533
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 177Lu-DOTATATE
Trial: 32091613
Drug: Pre‐emptive intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐emptive intrathecal morphine
Trial: 32091613
Drug: Post‐operative intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post‐operative intrathecal morphine
Trial: 32091613
Drug: Post‐operative intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post‐operative intrathecal morphine (Group III)
Trial: 32091613
Drug: Pre‐emptive intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐emptive intrathecal morphine (Group II)
Trial: 32131801
Drug: Biological management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological management of carious lesions and prevention (B + P)
Trial: 33362687
Drug: Mirror Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror Therapy
Trial: 33962762
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer carbonate (2400 mg) administered concomitantly with roxadustat (200 mg)
Trial: 33962762
Drug: Calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium acetate (1900 mg) administered concomitantly with roxadustat (200 mg)
Trial: 33962762
Drug: Roxadustat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (200 mg) administered 1 hour before sevelamer carbonate
Trial: 33962762
Drug: Roxadustat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (200 mg) administered 1 hour after sevelamer carbonate
Trial: 33962762
Drug: Roxadustat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (200 mg) administered 1 hour before calcium acetate
Trial: 33962762
Drug: Roxadustat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (200 mg) administered 1 hour after calcium acetate
Trial: 33962762
Drug: Roxadustat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (200 mg) administered 2 to 3 hours after sevelamer carbonate
Trial: 33962762
Drug: Roxadustat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (200 mg) administered 2 to 3 hours after calcium acetate
Trial: 32100576
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (15 minutes, twice a week)
Trial: 32112140
Drug: Focal and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal and peripheral laser treatment
Trial: 35963005
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ranibizumab with photodynamic therapy)
Trial: 33580636
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (cholecalciferol, 50,000 IU/dose)
Trial: 32609313
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid 180 mg once daily for 24 weeks